Literature DB >> 3115548

Vertebral collapse in juvenile chronic arthritis: its relationship with glucocorticoid therapy.

S Varonos1, B M Ansell, J Reeve.   

Abstract

Forty-six patients with juvenile chronic arthritis maintained on glucocorticoid therapy have been reviewed retrospectively for evidence of vertebral collapse. The 23 patients who had sustained vertebral fractures had received a daily dose 2.3 times higher than those without. No patients sustained a vertebral collapse until they had received a prednisolone cumulative dose of at least 5 g. It would appear that the ideal dose, if collapse of vertebrae is to be avoided, should be not more than 5 mgs daily, probably best given as 10 mg on alternate days; unfortunately, some children with serious systemic disease cannot be controlled on these low doses. In such cases it seems justified to investigate the possible use of the oxazoline derivative of prednisolone (deflazacort) in view of its reported bone-sparing properties in adults.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3115548     DOI: 10.1007/bf02555248

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  9 in total

1.  THE PRESENT STATUS OF STEROID TREATMENT IN RHEUMATOID ARTHRITIS.

Authors:  E G BYWATERS
Journal:  Proc R Soc Med       Date:  1965-08

2.  Fractures in Still's disease.

Authors:  B W BADLEY; B M ANSELL
Journal:  Ann Rheum Dis       Date:  1960-06       Impact factor: 19.103

3.  The syndrome of spinal osteoporosis.

Authors:  P D Saville
Journal:  Clin Endocrinol Metab       Date:  1973-07

4.  Alternate-day corticosteroid therapy in juvenile chronic polyarthritis.

Authors:  B M Ansell; E G Bywaters
Journal:  J Rheumatol       Date:  1974-06       Impact factor: 4.666

5.  Effects of prednisone and deflazacort on vertebral bone mass.

Authors:  C Gennari; B Imbimbo
Journal:  Calcif Tissue Int       Date:  1985-12       Impact factor: 4.333

6.  A simple X-ray method for monitoring progress of osteoporosis.

Authors:  K K Jensen; L Tougaard
Journal:  Lancet       Date:  1981-07-04       Impact factor: 79.321

7.  Bone rarefaction and crush fractures in juvenile chronic arthritis.

Authors:  U Elsasser; B Wilkins; R Hesp; D I Thurnham; J Reeve; B M Ansell
Journal:  Arch Dis Child       Date:  1982-05       Impact factor: 3.791

8.  Effect of prednisone on growth and bone mineral content in childhood glomerular disease.

Authors:  R W Chesney; R B Mazess; P Rose; D K Jax
Journal:  Am J Dis Child       Date:  1978-08

9.  Total body calcium in rheumatoid arthritis: effects of disease activity and corticosteroid treatment.

Authors:  D M Reid; N S Kennedy; M A Smith; P Tothill; G Nuki
Journal:  Br Med J (Clin Res Ed)       Date:  1982-07-31
  9 in total
  29 in total

1.  Childhood onset arthritis is associated with an increased risk of fracture: a population based study using the General Practice Research Database.

Authors:  J M Burnham; J Shults; R Weinstein; J D Lewis; M B Leonard
Journal:  Ann Rheum Dis       Date:  2006-04-20       Impact factor: 19.103

Review 2.  A systematic review and meta-analysis of glucocorticoid-induced osteoporosis in children.

Authors:  Karen E Hansen; Brian Kleker; Nasia Safdar; Christie M Bartels
Journal:  Semin Arthritis Rheum       Date:  2014-02-11       Impact factor: 5.532

Review 3.  Is there an effective treatment for glucocorticoid-induced osteoporosis?

Authors:  D T Villareal; R Civitelli; C Gennari; L V Avioli
Journal:  Calcif Tissue Int       Date:  1991-08       Impact factor: 4.333

4.  Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: a national observational study.

Authors:  Celia Rodd; Bianca Lang; Timothy Ramsay; Nathalie Alos; Adam M Huber; David A Cabral; Rosie Scuccimarri; Paivi M Miettunen; Johannes Roth; Stephanie A Atkinson; Robert Couch; Elizabeth A Cummings; Peter B Dent; Janet Ellsworth; John Hay; Kristin Houghton; Roman Jurencak; Maggie Larché; Claire LeBlanc; Kiem Oen; Claire Saint-Cyr; Robert Stein; David Stephure; Shayne Taback; Brian Lentle; Maryann Matzinger; Nazih Shenouda; David Moher; Frank Rauch; Kerry Siminoski; Leanne M Ward
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-01       Impact factor: 4.794

5.  Variable deficits of bone mineral despite chronic glucocorticoid therapy in pediatric patients with inflammatory diseases: a Glaser Pediatric Research Network study.

Authors:  Emily von Scheven; Catherine M Gordon; David Wypij; Marcia Wertz; Kerry T Gallagher; Laura Bachrach
Journal:  J Pediatr Endocrinol Metab       Date:  2006-06       Impact factor: 1.634

6.  Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders.

Authors:  A M Huber; I Gaboury; D A Cabral; B Lang; A Ni; D Stephure; S Taback; P Dent; J Ellsworth; C LeBlanc; C Saint-Cyr; R Scuccimarri; J Hay; B Lentle; M Matzinger; N Shenouda; D Moher; F Rauch; K Siminoski; L M Ward
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-04       Impact factor: 4.794

7.  Factors playing a role in the development of decreased bone mineral density in juvenile chronic arthritis.

Authors:  Reyhan Celiker; Serpil Bal; Aysin Bakkaloğlu; Eda Ozaydin; Turgay Coskun; Alp Cetin; Fitnat Dinçer
Journal:  Rheumatol Int       Date:  2003-03-12       Impact factor: 2.631

Review 8.  Glucocorticoid-induced osteoporosis in rheumatic diseases.

Authors:  Rosa Maria Rodrigues Pereira; Jozélio Freire de Carvalho; Ernesto Canalis
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

Review 9.  Long-term bone health in glucocorticoid-treated children with rheumatic diseases.

Authors:  Isabelle Rousseau-Nepton; Bianca Lang; Celia Rodd
Journal:  Curr Rheumatol Rep       Date:  2013-03       Impact factor: 4.592

Review 10.  Deflazacort. A review of its pharmacological properties and therapeutic efficacy.

Authors:  A Markham; H M Bryson
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.